Abstract: A method of manufacturing a catalyst material includes the steps of: providing a body having an open-porous foam structure and comprising at least a first metal or alloy; providing particles, each of which particles comprising at least a second metal or alloy; distributing the particles on the body; forming a structural connection between each of at least a subset of the particles and the body; and forming an oxide film on at least the subset of the particles and the body, wherein the oxide film has a catalytically active surface.

Abstract: The present invention relates to a new pestivirus useful in the fields of veterinary virology and vaccines. Specifically, it relates to an isolated polynucleotide originating from pestivirus and a pestivirus, to vaccines and medical uses thereof, to chimeric virus comprising the polynucleotide and to expression vectors for heterologous expression of polypeptides.

Abstract: The present invention relates to a new pestivirus useful in the fields of veterinary virology and vaccines. Specifically, it relates to an isolated polynucleotide originating from pestivirus and a pestivirus, to vaccines and medical uses thereof, to chimeric virus comprising the polynucleotide and to expression vectors for heterologous expression of polypeptides.

Abstract: An aircraft cabin arrangement for a passenger aircraft, extending along a cabin axis which runs centrally through the aircraft cabin arrangement, having a ceiling trim arrangement provided in the upwardly pointing part of the outer wall of the aircraft cabin arrangement and is arranged above the cabin axis, wherein the ceiling trim arrangement comprises a central ceiling panel element and lateral ceiling panel elements which have a panel element, wherein the central ceiling panel element is arranged vertically above the cabin axis, wherein the lateral ceiling panel elements adjoin the central ceiling panel element on both sides in the lateral direction perpendicularly with respect to the cabin axis, wherein one or more of the central ceiling panel element and the lateral ceiling panel elements has a flat lighting device which is embodied in a flat fashion such that it extends over a surface section of the ceiling panel element.

Abstract: An aircraft cabin arrangement for a passenger aircraft, extending along a cabin axis which runs centrally through the aircraft cabin arrangement, having a ceiling trim arrangement provided in the upwardly pointing part of the outer wall of the aircraft cabin arrangement and is arranged above the cabin axis, wherein the ceiling trim arrangement comprises a central ceiling panel element and lateral ceiling panel elements which have a panel element, wherein the central ceiling panel element is arranged vertically above the cabin axis, wherein the lateral ceiling panel elements adjoin the central ceiling panel element on both sides in the lateral direction perpendicularly with respect to the cabin axis, wherein one or more of the central ceiling panel element and the lateral ceiling panel elements has a flat lighting device which is embodied in a flat fashion such that it extends over a surface section of the ceiling panel element.

Abstract: The present invention relates to mutant Pestiviruses, and vaccines containing said viruses.

Abstract: Disclosed are viral variants exhibiting reduced sensitivity to particular agents including nucleoside analogues and immunological mediators such as immunoglobulins and immune cells. Also provided are hepatitis B virus (HBV) variants which exhibit a level of replication fitness in the presence of a nucleoside analogue similar to or greater than in the absence of the nucleoside analogue. The present invention also provides methods of treating HBV infection, including a method for identifying a need to change or otherwise alter an existing therapeutic regimen. Also disclosed are methods for monitoring the development in a subject of an increased HBV load in the presence of a nucleoside analogue. The present invention further provides the use of nucleoside analogue-resistant HBV variants which exhibit a similar or increased replication fitness in the presence of the nucleoside analogue compared to in the absence of the nucleoside analogue to screen for medicaments to treat HBV infection.